

Press release

Elos implements strategic acquisition to develop Medical Technology offering

Elos has acquired Microplast AB, which is active in the injection-moulding of medical technology products. The company injection-moulds thermoplastic precision parts on behalf of medical-technology and biotechnology customers. The operation is located in Skara, Sweden and has 16 employees. The company has sales of slightly more than SEK 25 million, with favourable profitability.

Microplast has expertise in small parts of 0.01-25 gram, with close tolerances. The plastic materials used mainly comprise high-temperature and chemical-resistant plastics. To be able to manage these various types of material characteristics, Microplast has highly developed tool-design competencies. Similarly, it has broad-based production-technology experience of how various types of materials should be handled. Production is highly automated.

The operations and competencies represented by Microplast complement Elos Medtech's operations. Several Elos Medtech customers also purchase injection-moulded parts with high-precision requirements.

"The acquisition of Microplast is a key strategic step in the development of our offering of being a competent development and production partner in medical technology. The company favourably complements Elos' medical-technology operations. We are gaining access to the competencies required to mould and injection-mould small parts with close tolerances, thus complementing our precision-mechanics expertise in the Medical Technology business area. As a result of the acquisition, we expect to gradually be able to expand our total-package undertaking to encompass several of the Group's customers," says Göran Brorsson, Chief Executive Officer of Elos. "Microplast will also contribute interesting new customers to the Group, several of whom are market leaders in their areas."

The acquisition of Microplast becomes effective on 1 July 2011. The company will be included in the Medical Technology business area. The acquisition is estimated to have a positive effect on earnings per share during 2011.

Lidköping, 30 June 2011

Elos AB (publ)

For further information, please contact:
Göran Brorsson, CEO, +46 510 48 43 65, +46 70 511 78 60.

Elos' operations comprise development, manufacturing and marketing to international customers who need complex products used in demanding environments in the Medical Technology and Metrology business areas. For additional information, visit www.elos.se

The information contained in this press release is of the kind that Elos AB has to make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act.
The information was made public on 30 June 2011 at 17:00 pm (CET).